Entry Point Capital, LLC Janux Therapeutics, Inc. Transaction History
Entry Point Capital, LLC
- $221 Million
- Q4 2024
A detailed history of Entry Point Capital, LLC transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Entry Point Capital, LLC holds 12,225 shares of JANX stock, worth $454,403. This represents 0.3% of its overall portfolio holdings.
Number of Shares
12,225Holding current value
$454,403% of portfolio
0.3%Shares
2 transactions
Others Institutions Holding JANX
# of Institutions
187Shares Held
41MCall Options Held
115KPut Options Held
681K-
Ra Capital Management, L.P. Boston, MA9.17MShares$341 Million5.81% of portfolio
-
Janus Henderson Group PLC London, X02.52MShares$93.8 Million0.06% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY2.4MShares$89.2 Million3.93% of portfolio
-
Black Rock Inc. New York, NY2.34MShares$87.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.14MShares$79.4 Million0.0% of portfolio
About Janux Therapeutics, Inc.
- Ticker JANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,663,000
- Market Cap $1.55B
- Description
- Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...